Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU study aims to halt Alzheimer’s by blocking enzyme

16.03.2006


Inhibiting gamma secretase may prevent amyloid plaque build-up thought to trigger disease, but trials continue



Oregon Health & Science University is participating in a national study of a drug that may prevent Alzheimer’s disease by blocking an enzyme that produces plaques believed to trigger the disorder.

OHSU is one of six sites around the country taking part in a double-blind, placebo-controlled study of the agent known as LY450139, a gamma secretase inhibitor manufactured by Indianapolis-based Eli Lilly and Co. Other study sites are in Indianapolis, St. Louis, Philadelphia, Seattle, and La Jolla, Calif. Lilly is funding the study.


Gamma secretase is an enzyme that produces beta-amyloid by snipping a fragment of the protein from a larger protein that extends across the plasma membrane of the cell. The beta-amyloid fragments clump together to form dense, insoluble plaques inside the hippocampus, a curved, elongated ridge deep in the brain that controls learning and memory, and the cerebral cortex, the surface layer of gray matter of the cerebrum where sensory and motor information is coordinated.

The gamma secretase enzyme is made up of a complex of four proteins, and LY450139 is thought to de-activate it by binding within the complex, although the exact location is still being studied.

"There is a theory that beta-amyloid produces Alzheimer’s disease, so if you stop the amyloid, you stop the disease," said Joseph Quinn, M.D., associate professor of neurology, and cell and developmental biology, OHSU School of Medicine and the Portland Veterans Affairs Medical Center. He also is an investigator at OHSU’s Layton Aging & Alzheimer’s Disease Center.

The study is "focused on the presumed underlying cause of the disease instead of symptoms. This is the beginning of the ’anti-amyloid’ era of Alzheimer’s disease treatment, attacking what are thought to be the roots of the disease," Quinn said.

The 29-week-long study, set for completion in September, is a Phase II trial involving 45 participants that will determine LY450139’s safety, whether it causes any side effects, how much of the drug should be given and how long it can be detected in the blood. Researchers hope to measure levels of biomarkers in blood and spinal fluid that might relate to Alzheimer’s disease, changes in the study subjects’ thinking and memory, and changes in their daily living activities.

Study participants will be asked to make an initial office visit, followed by visits for treatments every other week for 14 weeks. They then will make two follow-up visits.

In a study co-authored by Quinn and published in the Feb. 28 issue of the journal Neurology, LY450139 was shown to reduce blood plasma levels of beta-amyloid by 38 percent in 70 Alzheimer’s patients given 30 milligrams of LY450139 for one week, followed by 40 milligrams for five weeks. They reported that the lowest concentration of the protein occurred three hours after a 40 milligram dose was taken. The drug also was well tolerated.

"This study involved active treatment for only six weeks," Quinn said. "Clinical outcomes were not expected to change. This was the first step toward a trial intended to achieve clinical effects." OHSU was the largest recruiter for the study, enrolling 14 of the 70 participants.

A study published last summer in the journal Clinical Neuropharmacology found results similar to those in the Neurology study. In that Phase I trial, researchers saw a "dose-dependent" reduction blood plasma levels of beta-amyloid in 37 volunteers taking between 5 and 50 milligrams of LY450139 during a 14-day period. Side effects, which can include headache and abdominal pain, were manageable.

Eric Siemers, M.D., a neurologist at Eli Lilly and lead investigator for the Neurology and Clinical Neuropharmacology studies, said his company has been interested in finding therapies for Alzheimer’s disease "for a number of years," and that LY450139 is "the first putative disease-modifying drug" to reach the clinical trial stage.

But that doesn’t mean a therapy that will stop the cognitive decline caused by Alzheimer’s disease is right around the corner, Siemers emphasized.

"The current study is primarily to look at tolerability, and also to confirm the biomarkers effects," he said. "Studies that look at clinical measures of cognitive decline in Alzheimer’s disease patients typically require 12 to 18 months of treatment, and hundreds of subjects."

According to OHSU’s Layton Aging and Alzheimer’s Disease Center, 76,000 Oregonians are among an estimated 4.5 million Americans who have Alzheimer’s disease, the most common form of dementia, or a related disorder. These dementias are especially common with increasing age and are expected to afflict half of those 85 and older in the coming years.

Jonathan Modie | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Biocompatible 3-D tracking system has potential to improve robot-assisted surgery

17.02.2017 | Medical Engineering

Real-time MRI analysis powered by supercomputers

17.02.2017 | Medical Engineering

Antibiotic effective against drug-resistant bacteria in pediatric skin infections

17.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>